Tissue-type plasminogen activator (t-PA) is a promising thrombolytic agent because it can produce thrombolysis without inducing a plasma proteolytic state. It is uncertain if this potentially important feature renders t-PA less hemorrhagic than other plasminogen activators. We have compared the hemorrhagic and thrombolytic effects of t-PA and streptokinase in rabbits. Streptokinase, 4000 U/kg/h...

To determine the distribution of antibodies to streptokinase that might be anticipated in patients requiring treatment with streptokinase, specific anti-streptokinase antibody titres were determined in a group of subjects from the general population and in a group of patients presenting with acute myocardial infarction. Enzyme-linked immunosorbent assays were developed to measure specific anti-...

A patient developed serum sickness and acute renal failure following therapy with streptokinase for myocardial ischaemia. There was a previous history of a cellulitic infection of the leg, and antibodies to streptokinase were measurable in a serum sample taken from the patient before therapy. A cryoglobulin was detected at the time of presentation with serum sickness. This contained polyclonal ...

In the GISSI trial, 11,712 patients with acute myocardial infarction were randomized to receive either standard care or standard care with 1.5 million units streptokinase intravenously. A highly significant reduction in mortality during hospitalization in streptokinase-treated patients was observed. The mortality at 1 year was determined in 98.3% of the patients who had been originally randomiz...

THROMBOLYTIC THERAPY in patients with acute myocardial infarction has received renewed attention since intracoronary infusion of streptokinase has been introduced into clinical practice. Efficacy of intracoronary infusion of streptokinase. In-tracoronary infusion of streptokinase results in recana-lization of approximately 75% of completely obstructed infarct-related vessels" 2 (table 1). Modif...

OBJECTIVE To evaluate the role of intrapleural streptokinase in the management of complicated parapneumonic effusions in children. DESIGN Prospective comparative study. SETTING Cheng Kung University Hospital, a tertiary medical center in Tainan, Taiwan. PATIENTS AND METHODS We enrolled as our prospective study group 20 consecutive children with complicated parapneumonic effusions who rece...

BACKGROUND AND PURPOSE We used 99mTc-hexamethylpropyleneamine oxime single-photon emission computed tomography (SPECT) to study cerebral perfusion in patients treated with streptokinase for acute ischemic stroke in an open and prospective study. Our primary aims were (1) to compare the extent of reperfusion between patients who had received thrombolytic therapy and a control group studied durin...

The activation of human plasminogen by streptokinase has been the subject of extensive investigation (4-8). There appears to be general agreement that at least two enzymatic activities are demonstrable in streptokinase-plasminogen reaction mixtures. One is the proteolytic enzyme human plasmin, characterized in part by its ability to hydrolyze lysine and arginine esters and protein substrates su...

Streptokinase (SK) is being increasingly used in the treatment of acute myocardial infarction and ischemic stroke. The feeding control method using substrate balance equations is vital to maintain the preferred specific growth rate for the high-level expression of recombinant proteins. In this study, initial experiments on chemical and temperature inducible expression systems were carried out t...

Peak serum C-reactive protein concentrations were measured in 146 patients randomized to receive streptokinase, alteplase, or a combination of streptokinase and alteplase in the GUSTO-I trial. Those receiving alteplase treatment had lower values than those receiving streptokinase or the combination treatment. Irrespective of treatment, complete reperfusion of the infarct-related artery (TIMI gr...